Vaccinating in the Emergency Department, a Model to Overcome Influenza Vaccine Hesitancy.
Journal
Pediatric quality & safety
ISSN: 2472-0054
Titre abrégé: Pediatr Qual Saf
Pays: United States
ID NLM: 101702480
Informations de publication
Date de publication:
Historique:
received:
10
08
2020
accepted:
01
01
2021
entrez:
15
4
2021
pubmed:
16
4
2021
medline:
16
4
2021
Statut:
epublish
Résumé
Vaccine hesitancy and delays in vaccine administration time have limited the success of prior influenza vaccination initiatives in the pediatric emergency department (ED). In 2018-2019, season 1, this ED implemented mandatory vaccine screening and offered the vaccine to all eligible patients; however, only 9% of the eligible population received the vaccine. In 2019-2020, season 2, the team sought to improve influenza vaccination rates from 9% to 15% and administer over 2,000 vaccines to eligible ED patients. Key drivers included: identifying vaccine hesitancy, providing counseling, reducing administration delays, and developing reminders for vaccine administration. We tested interventions using plan-do-study-act cycles. We included discharged ED patients, age 6 months-18 years old, emergency severity index score 2-5, and no prior vaccine this season. Process measures included percent of patients screened, eligible, accepting the vaccine, and leaving before vaccination. Outcome measures were the percent of eligible patients vaccinated and the total number of vaccines administered. Vaccination time was the balancing measure. We included 57,804 children in this study. Comparing season 1 to 2, screening rates (84%) and eligibility rates (58%) were similar. Vaccine acceptance rates improved from 13% to 22%, the proportion of patients leaving before vaccination decreased from 32% to 17%, and vaccination rates improved from 9% to 20%. Total vaccines administered increased from 1,309 to 3,180, and vaccination time was 5 minutes faster in season 2. This ED influenza vaccination process provides a model to overcome vaccine hesitancy and can be adapted and replicated for any vaccine-preventable illness.
Identifiants
pubmed: 33855251
doi: 10.1097/pq9.0000000000000430
pmc: PMC8032353
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e430Informations de copyright
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
Disclosure The authors have no financial interest to declare in relation to the content of this article.
Références
Public Health Rep. 2020 Sep/Oct;135(5):640-649
pubmed: 32783780
JAMA. 2020 Jun 23;323(24):2458-2459
pubmed: 32421155
Pediatr Emerg Care. 2020 Nov;36(11):e641-e645
pubmed: 31913247
Pediatr Emerg Care. 1992 Apr;8(2):98-104
pubmed: 1603711
Vaccine. 2015 Apr 8;33(15):1802-7
pubmed: 25744225
Pediatr Emerg Care. 2019 Jul;35(7):493-497
pubmed: 31206505
Vaccine. 2012 Mar 23;30(14):2448-52
pubmed: 22300721
JAMA Pediatr. 2018 Jan 2;172(1):e173879
pubmed: 29114729
Pediatr Emerg Care. 1995 Dec;11(6):340-6
pubmed: 8751167
J Adolesc Health. 2011 Aug;49(2):133-40
pubmed: 21783044
Pediatr Qual Saf. 2020 Jul 08;5(4):e322
pubmed: 32766495